文献速递药物不良反应与药物警戒

质子泵抑制剂相关性与功能障碍:VigiBase药物警戒数据库分析

Sexual Dysfunctions Associated with Proton Pump Inhibitors: Insights from VigiBase, the World Health Organization Pharmacovigilance Database.
PubMed 文献 · Drug Saf · 2025-10-31

基于WHO VigiBase数据库,截至2024年9月4日共收集420598份PPI相关个体病例安全报告,其中841份含性与功能障碍信息。 disproportionately分析显示奥美拉唑与勃起功能障碍报告显著相关(调整ROR 1.76,95%CI 1.54-2.01),艾司奥美拉唑在女性中与生殖器不适(ROR 3.66,95%CI 1.34-10.04)和雌激素缺乏(ROR 3.80,95%CI 1.03-13.99)相关。亚组分析(18-64岁)确认奥美拉唑致勃起功能障碍信号(调整ROR 1.80,95%CI 1.49-2.16),并发现奥美拉唑致性欲下降(调整ROR 1.49,95%CI 1.05-2.12)、艾司奥美拉唑致性腺功能减退(调整ROR 5.22,95%CI 1.22-22.34)及奥美拉唑致女性生殖器不适(调整ROR 3.55,95%CI 1.13-11.09)等新信号。结论提示PPI可能致性与功能障碍信号,需进一步观察性研究验证。

要点

  • 奥美拉唑与勃起功能障碍报告显著相关(调整ROR 1.76,95%CI 1.54-2.01)
  • 艾司奥美拉唑在女性中与生殖器不适和雌激素缺乏报告显著相关
  • 亚组分析发现奥美拉唑致性欲下降、艾司奥美拉唑致性腺功能减退等新信号

核心结论

  • 本研究提示PPI使用与性与功能障碍存在安全性信号,包括勃起功能障碍、生殖器不适和雌激素缺乏。
  • 需进一步观察性研究验证和表征这些潜在安全性信号。

研究设计与样本

  • 基于WHO国际药物警戒数据库VigiBase的病例-非病例 disproportionality分析。
  • 纳入截至2024年9月4日所有含PPI(奥美拉唑、兰索拉唑、雷贝拉唑、泮托拉唑、艾司奥美拉唑)作为可疑或相互作用药物的性与功能障碍个体病例安全报告。
  • 共收集420598份PPI相关个体病例安全报告,其中841份含性与功能障碍信息并报告性别。
  • 采用报告比值比(ROR)及95%置信区间,经Bonferroni校正多重检验。
  • 亚组分析限制年龄18-64岁以控制年龄对性功能的影响。

主要发现

  • 总体分析:奥美拉唑与勃起功能障碍报告显著相关(调整ROR 1.76;95%CI 1.54-2.01)。
  • 总体分析:艾司奥美拉唑在女性中与生殖器不适(ROR 3.66;95%CI 1.34-10.04)和雌激素缺乏(ROR 3.80;95%CI 1.03-13.99)报告显著相关。
  • 亚组分析(18-64岁):确认奥美拉唑致勃起功能障碍信号(调整ROR 1.80;95%CI 1.49-2.16)。
  • 亚组分析:发现奥美拉唑致性欲下降(调整ROR 1.49;95%CI 1.05-2.12)和艾司奥美拉唑致性腺功能减退(调整ROR 5.22;95%CI 1.22-22.34)在男性中的新信号。
  • 亚组分析:发现奥美拉唑致女性生殖器不适(调整ROR 3.55;95%CI 1.13-11.09)的新信号。

临床怎么用

  • 临床遇到性与功能障碍患者时,应询问PPI使用史并考虑药物相关可能性。
  • 对使用奥美拉唑或艾司奥美拉唑的患者,关注勃起功能障碍、生殖器不适、性欲下降等不良反应。

局限性

  • 研究为基于自发报告数据库的disproportionality分析,不能确立因果关系。
  • 存在报告偏倚、混杂因素及未控制潜在混杂变量等局限。
  • 需进一步观察性研究验证和表征这些潜在安全性信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Over the years, several observational studies and case reports have been published hypothesizing a potential association between the use of proton pump inhibitors (PPIs) and sexual dysfunctions in both male and female patients. OBJECTIVES: We aimed to investigate the potential association between PPI use and sexual dysfunction onset using VigiBase, the World Health Organization international pharmacovigilance database. METHODS: All individual case safety reports of sexual dysfunctions containing PPIs (i.e. omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole) as suspected or interacting drugs until 4 September, 2024 were selected from VigiBase using the Standardised MedDRA Query "Sexual dysfunction". A descriptive analysis of the selected individual case safety reports was carried out. Potentially new safety signals were identified through a disproportionality analysis and calculated as a reporting odds ratio (ROR) along with a 95% confidence interval (CI), which were adjusted via Bonferroni correction for multiple testing. To account for age-related effects on sexual functions, a subgroup analysis was carried out by restricting the study population only to patients aged from 18 to 64 years. RESULTS: A total of 420,598 individual case safety reports concerning PPIs were collected in VigiBase during the study period. Of these, 841 containing at least one Preferred Term included in the "Sexual dysfunction" Standardised MedDRA Query reporting information on sex were retrieved. Overall, disproportionate reporting for omeprazole concerning erectile dysfunction (adjusted ROR, 1.76; 95% CI 1.54-2.01) was observed, while two statistically significant adjusted RORs for esomeprazole, i.e. genital discomfort (ROR, 3.66; 95% CI 1.34-10.04) and oestrogen deficiency (ROR, 3.80; 95% CI 1.03-13.99) in female patients were found. The subgroup analysis confirmed the statistically significant disproportionate reporting of erectile dysfunction for omeprazole (adjusted ROR: 1.80; 95% CI 1.49-2.16), and generated new potential safety signals including an omeprazole-induced libido decrease (adjusted ROR, 1.49; 95% CI 1.05-2.12) and esomeprazole-induced hypogonadism (adjusted ROR, 5.22; 95% CI 1.22-22.34) in male individuals, and omeprazole-induced genital discomfort (adjusted ROR, 3.55; 95% CI 1.13-11.09) in female individuals. CONCLUSIONS: Findings of this study suggest the presence of safety signals of PPI-induced sexual dysfunctions, such as erectile dysfunction, genital discomfort and oestrogen deficiency. However, further observational studies are required to validate and further characterise these potential safety signals.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Crisafulli S, Ciccimarra F, Scapini F, et al. Sexual Dysfunctions Associated with Proton Pump Inhibitors: Insights from VigiBase, the World Health Organization Pharmacovigilance Database. Drug Saf. 2025. PMID: 41171556. doi:10.1007/s40264-025-01626-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。